{"id":5345,"date":"2024-12-17T00:11:44","date_gmt":"2024-12-17T00:11:44","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=rkd-news&#038;p=5345"},"modified":"2025-10-14T13:10:27","modified_gmt":"2025-10-14T13:10:27","slug":"asn-2024-spotlight-sparsentan-complete-remission","status":"publish","type":"rkd-news","link":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/","title":{"rendered":"ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n    <img decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png\" class=\"a-img a-img--right h-full\" alt=\"Hero Section Background Image\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>    <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\r\n\t<section style=\"padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;margin-top:calc(-120px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\"><\/i> Published on December 23, 2024\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics: <\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\n\t\t<div class=\"info-block-box\">\n\t\t\t\n\t\t\t\t\t<\/div>\n\n\t\t\n\t\t<div class=\"info-block-share\">Share:\n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Fasn-2024-spotlight-sparsentan-complete-remission%2F&#038;text=ASN+2024+Spotlight%3A+New+Treatment+Targets+in+IgA+Nephropathy\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Fasn-2024-spotlight-sparsentan-complete-remission%2F&#038;title=ASN+2024+Spotlight%3A+New+Treatment+Targets+in+IgA+Nephropathy\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Fasn-2024-spotlight-sparsentan-complete-remission%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=ASN%202024%20Spotlight%3A%20New%20Treatment%20Targets%20in%20IgA%20Nephropathy&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Fasn-2024-spotlight-sparsentan-complete-remission%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div class=\"modal modal-request-copy\" style=\"display: none;\" id=\"modal-request-copy\">\n\t<div class=\"modal__backdrop\">\n\t\t<div class=\"modal__card\">\n\t\t\t<button class=\"modal__close btn-close\" aria-label=\"Close modal\">&times;<\/button>\n\t\t\t<h4 class=\"has-heading-3-font-size\">Request a copy<\/h4>\n\t\t\t\n<div class=\"wpcf7 no-js\" id=\"wpcf7-f2317-o1\" lang=\"en-US\" dir=\"ltr\" data-wpcf7-id=\"2317\">\n<div class=\"screen-reader-response\"><p role=\"status\" aria-live=\"polite\" aria-atomic=\"true\"><\/p> <ul><\/ul><\/div>\n<form action=\"\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/5345#wpcf7-f2317-o1\" method=\"post\" class=\"wpcf7-form init wpcf7-acceptance-as-validation\" aria-label=\"Contact form\" novalidate=\"novalidate\" data-status=\"init\">\n<fieldset class=\"hidden-fields-container\"><input type=\"hidden\" name=\"_wpcf7\" value=\"2317\" \/><input type=\"hidden\" name=\"_wpcf7_version\" value=\"6.1.1\" \/><input type=\"hidden\" name=\"_wpcf7_locale\" value=\"en_US\" \/><input type=\"hidden\" name=\"_wpcf7_unit_tag\" value=\"wpcf7-f2317-o1\" \/><input type=\"hidden\" name=\"_wpcf7_container_post\" value=\"0\" \/><input type=\"hidden\" name=\"_wpcf7_posted_data_hash\" value=\"\" \/>\n<\/fieldset>\n<div class=\"cf7-fields-wrapper\">\n  <div class=\"form-two-cols\">\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-first-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-first-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"First Name*\" value=\"\" type=\"text\" name=\"request-first-name\" \/><\/span>\n    <\/div>\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-last-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-last-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Last Name*\" value=\"\" type=\"text\" name=\"request-last-name\" \/><\/span>\n    <\/div>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-your-email\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-email wpcf7-validates-as-required wpcf7-text wpcf7-validates-as-email\" id=\"request-your-email\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Email*\" value=\"\" type=\"email\" name=\"request-your-email\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-title\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Title*\" value=\"\" type=\"text\" name=\"request-title\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-agree\"><span class=\"wpcf7-form-control wpcf7-acceptance\"><span class=\"wpcf7-list-item\"><label><input type=\"checkbox\" name=\"request-agree\" value=\"1\" class=\"required\" id=\"request-agree\" aria-invalid=\"false\" \/><span class=\"wpcf7-list-item-label\">All personal data will be processed by or on behalf of Travere to provide access to company information and to respond to requests. Travere will retain personal data only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal data is private and will not disseminate it to third parties who are not providing services to Travere. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\">Travere privacy policies<\/a>.<\/span><\/label><\/span><\/span><\/span>\n  <\/div>\n  <div class=\"form-group text-right\">\n    <input class=\"wpcf7-form-control wpcf7-submit has-spinner btn\" id=\"request-submit\" type=\"submit\" value=\"Yes, continue\" \/>\n  <\/div>\n<\/div><div class=\"wpcf7-response-output\" aria-hidden=\"true\"><\/div>\n<\/form>\n<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div> <\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(30px * var(--scale));padding-right:0px;padding-bottom:0px;padding-left:0px;\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">In this issue we: <\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li><a href=\"#h-proteinuria-is-the-single-strongest-modifiable-prognostic-indicator-for-measuring-progression-of-iga-nephropathy-1-2\">Discuss the importance of proteinuria as a biomarker and the proposed lower proteinuria goals from the draft 2024 KDIGO (Kidney Disease: Improving Global Outcomes) guideline<\/a><\/li>\n<li><a href=\"#h-asn-2024-data-suggest-that-sparsentan-can-achieve-2024-draft-kdigo-guideline-proteinuria-treatment-goals-in-multiple-iga-nephropathy-patient-populations-1-5-7\">Highlight sparsentan data from ASN 2024 showing the impact of lower proteinuria on kidney preservation in multiple IgA nephropathy populations<\/a><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"event-video\" id=\"video\">\n\t\t\t<p class=\"has-heading-3-font-size\">Welcome by Dr. Corey Cavanaugh<\/p>\n\t\t\n\t<a href=\"#\" class=\"event-video--img\" style=\"background-image: url('https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/Web-banner.png');\">\n\t\t<span class=\"icon2-play\" aria-hidden=\"true\"><\/span>\n\t<\/a>\n\t\n\t<div class=\"event-video--vimeo\"><\/div>\n\t\n\t<\/div>\n\n<script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script>\n<script>\n\tdocument.addEventListener(\"DOMContentLoaded\", function() {\n\t\tconst imgLink = document.querySelector(\".event-video--img\");\n\t\tconst vimeoDiv = document.querySelector(\".event-video--vimeo\");\n\t\tlet iframeExists = false;\n\t\tlet player;\n\n\t\timgLink.addEventListener(\"click\", function(event) {\n\t\t\tevent.preventDefault();\n\n\t\t\tif (!iframeExists) {\n\t\t\t\tconst iframe = document.createElement(\"iframe\");\n\t\t\t\tiframe.src = \"https:\/\/player.vimeo.com\/video\/1041175884\";\n\t\t\t\tiframe.frameBorder = \"0\";\n\t\t\t\tiframe.allow = \"autoplay; fullscreen\";\n\t\t\t\tiframe.allowFullscreen = true;\n\t\t\t\tvimeoDiv.appendChild(iframe);\n\t\t\t\t\n\t\t\t\tplayer = new Vimeo.Player(iframe);\n\t\t\t\tplayer.play();\n\t\t\t\tiframeExists = true;\n\t\t\t}\n\n\t\t\tvimeoDiv.style.display = \"block\";\n\t\t\timgLink.style.display = \"none\";\n\t\t});\n\n\t\tvimeoDiv.addEventListener(\"click\", function() {\n\t\t\tconst iframe = vimeoDiv.querySelector(\"iframe\");\n\t\t\tiframe.contentWindow.postMessage('{\"method\":\"play\"}', 'https:\/\/player.vimeo.com\/video\/1041175884');\n\t\t});\n\t});\n<\/script><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-proteinuria-is-the-single-strongest-modifiable-prognostic-indicator-for-measuring-progression-of-iga-nephropathy-1-2\" style=\"padding-top:calc(30px * var(--scale))\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Proteinuria is the single strongest modifiable prognostic indicator for measuring progression of IgA nephropathy<sup>1,2<\/sup><\/span><\/mark><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>To prolong kidney survival and address the <a href=\"https:\/\/clleancode.top\/travere-redesign\/episode\/unmet-needs-in-igan\/\" target=\"_blank\" rel=\"noopener\">clinical unmet needs of IgA nephropathy<\/a>, the evolving care paradigm emphasizes lowering proteinuria goals.<sup>3,4<\/sup><\/p>\n<p>Proteinuria is established as the only validated biomarker for measuring IgA nephropathy progression.<sup>1-3<\/sup> We now know that patients traditionally considered low risk for disease progression (i.e. proteinuria levels <1.0 g\/day) treated with renin-angiotensin system inhibitors (RASi) often progress to kidney failure within 10 years as demonstrated by data from the <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/long-term-outcomes-in-iga-nephropathy-2\/\" target=\"_blank\" rel=\"noopener\">IgA nephropathy cohort in the RaDaR study<\/a>.<sup>4<\/sup><\/p>\n<p>The newly released draft 2024 KDIGO guideline recommends targeting proteinuria levels <0.5 g\/day, preferably <0.3 g\/day (complete remission [CR]) to prolong kidney survival.<sup>3<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-asn-2024-data-suggest-that-sparsentan-can-achieve-2024-draft-kdigo-guideline-proteinuria-treatment-goals-in-multiple-iga-nephropathy-patient-populations-1-5-7\" style=\"padding-top:calc(30px * var(--scale))\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">ASN 2024 data suggest that sparsentan can achieve 2024 draft KDIGO guideline proteinuria treatment goals in multiple IgA nephropathy patient populations<sup>1,5-7<\/sup><\/span><\/mark><\/h3>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Safety and efficacy of sparsentan in patients with IgA nephropathy was established in <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protect-2-year-results-sparsentan-vs-irbesartan-iga-nephropathy\/\" target=\"_blank\" rel=\"noopener\">PROTECT, an active-controlled Phase 3 study<\/a>.<sup>8<\/sup> Patients treated with sparsentan in the PROTECT study were nearly three times more likely to achieve CR (<0.3 g\/day) as compared to those treated with maximum labeled dose irbesartan.<sup>8<\/sup><\/p>\n<p>At ASN 2024, additional PROTECT analyses demonstrated the importance of lowering proteinuria and the clinical implications of using sparsentan to reach proteinuria remission in various IgA nephropathy patient populations.<sup>5,6<\/sup><\/p>\n<p>In a PROTECT <em>post hoc<\/em> analysis of proteinuria remission, the kidney function of patients achieving or not achieving CR were assessed.<sup>5<\/sup>\u00a0 Regardless of whether randomized to active control (i.e. irbesartan) or sparsentan, patients who achieved urinary protein excretion (UPE) <0.5 g\/day showed a slower estimated glomerular filtration rate (eGFR) decline indicating that reaching low proteinuria target levels was predictive of better long-term kidney function.<sup>5<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024-.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"8211\" height=\"5594\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024-.png\" class=\"attachment-full size-full\" alt=\"Line graph depicting absolute change from baseline in eGFR at each study visit in patients who did or did not achieve UPE\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024-.png 8211w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024--300x204.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024--1024x698.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024--768x523.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024--1536x1046.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024--2048x1395.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-egfr-figure-Dec-2024--290x198.webp 290w\" sizes=\"auto, (max-width: 8211px) 100vw, 8211px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<p class=\"has-small-font-size\"><strong>Figure. PROTECT post hoc analysis: Absolute change from baseline in eGFR at each study visit in patients who did or did not achieve UPE &lt;0.5 g\/day<sup>5a<\/sup><\/strong><br><sup>a<\/sup>Change from baseline in eGFR by visit using a mixed models for&nbsp;repeated measures (MMRM) with on-study values and baseline UPE adjustment.<sup>5<\/sup><\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In PROTECT, 37% (151\/404) of patients, irrespective of treatment assignment, achieved UPE &lt;0.5 g\/day at any time during the study.<sup>5<\/sup> Of those who achieved UPE&lt;0.5 g\/day, 68% (103\/151) of patients were treated with sparsentan, and 32% (48\/151) were treated with maximum labeled dose irbesartan.<sup>5<\/sup><br><br>Explore more data from the <a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span style=\"text-decoration: underline;\">PROTECT <em>post hoc<\/em> analysis of proteinuria remission<\/span><\/mark><\/a>.<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"8211\" height=\"5594\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024.png\" class=\"attachment-full size-full\" alt=\"Pie chart depicting patients in PROTECT who achieved UPE\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024.png 8211w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024-300x204.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024-1024x698.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024-768x523.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024-1536x1046.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024-2048x1395.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-eGFR-PROTECT-UPE-at-any-time-figure-Dec-2024-290x198.webp 290w\" sizes=\"auto, (max-width: 8211px) 100vw, 8211px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-small-font-size\"><strong>Figure. PROTECT <em>post hoc<\/em> analysis: Patients who achieved UPE &lt;0.5 g\/day at any time through Week 110<sup>5<\/sup><\/strong><\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In a separate <em>post hoc<\/em> subgroup analysis, the probability of achieving CR at any time during the study by baseline urine protein-creatinine ratio (UPCR) values above and below 1.0 g\/g was studied.<sup>6<\/sup><br><br>In this analysis, CR was achieved earlier and more frequently in patients treated with sparsentan versus irbesartan, regardless of baseline UPCR level.<sup>6<\/sup><br><br>Explore more data from this <a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/\" target=\"_blank\" rel=\"noreferrer noopener\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span style=\"text-decoration: underline;\">PROTECT <em>post hoc<\/em> subgroup analysis<\/span><\/mark><\/a>.<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"8211\" height=\"5593\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024.png\" class=\"attachment-full size-full\" alt=\"Bar graph depicting patients who achieved UPE\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024.png 8211w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024-300x204.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024-1024x698.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024-768x523.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024-1536x1046.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024-2048x1395.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-newsletter-UPEUPCR-figure-Dec-2024-290x198.webp 290w\" sizes=\"auto, (max-width: 8211px) 100vw, 8211px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-small-font-size\"><strong>Figure. PROTECT <em>post hoc<\/em> subgroup analysis: Patients who achieved UPE &lt;0.5 g\/day by baseline UPCR level<sup>6<\/sup><\/strong><\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In PROTECT and its <em>post hoc<\/em> analyses, patients receiving sparsentan had greater proteinuria reduction and achieved proteinuria remission earlier and more frequently than patients on maximum labeled dose irbesartan, and sparsentan slowed the rate of eGFR decline to a greater degree regardless of baseline UPCR.<sup>5,6,8<\/sup><br><br>Sparsentan was well tolerated with a comparable safety profile to maximum labeled dose irbesartan.<sup>5,6<\/sup><br><br>While PROTECT showed the importance of complete proteinuria remission in previously treated patients with IgA nephropathy, the interim analysis of SPARTAN, a Phase 2, open-label, single arm, multicenter trial, demonstrated the effect of sparsentan in treatment-naive patients.<sup>5-7<\/sup><br><br>Newly diagnosed patients being treated with sparsentan experienced rapid and sustained reduction in proteinuria (approximately 70% from baseline).<sup>7<\/sup> Of those patients, 75% (9\/12) achieved UPE &lt;0.5 g\/day at any time point in the 24-week SPARTAN study.<sup>7<br><\/sup><br>No new safety signals were identified in this interim analysis of SPARTAN data.<sup>7<\/sup><br><br>Explore more data from the <a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/spartan-igan-first-line-interim-analysis\/\" target=\"_blank\" rel=\"noreferrer noopener\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span style=\"text-decoration: underline;\">SPARTAN interim analysis<\/span><\/mark><\/a>.<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"8211\" height=\"5593\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024.png\" class=\"attachment-full size-full\" alt=\"Pie chart depicting patients who achieved and did not achieve UPE\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024.png 8211w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024-300x204.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024-1024x698.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024-768x523.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024-1536x1046.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024-2048x1395.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/RKD-Newsletter-SPARTAN-UPE-figure-Dec-2024-290x198.webp 290w\" sizes=\"auto, (max-width: 8211px) 100vw, 8211px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-small-font-size\"><strong>Figure. SPARTAN interim analysis: Patients who achieved UPE &lt;0.5 g\/day at any point in the 24-week study<sup>7<\/sup><\/strong><\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In conclusion, data from the PROTECT and SPARTAN analyses demonstrated that patients on sparsentan can reach the proteinuria treatment goals outlined in the 2024 KDIGO draft guideline, benefitting multiple patient populations including<sup>1,5-7<\/sup>:<\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>Previously treated patients<\/li>\n\n\n\n<li>Patients once considered low risk (UPCR &lt;1.0 g\/day)<\/li>\n\n\n\n<li>Treatment-na\u00efve patients<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-group is-layout-constrained wp-block-group-is-layout-constrained\">\n<p><\/p>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-left paragraph-border\" id=\"h-asn-kidney-week-2024\" style=\"padding-bottom:calc(20px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">ASN Kidney Week 2024<\/mark><\/span><\/h4>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">Learn more about Travere Therapeutics\u2019 data from ASN 2024<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\"><!DOCTYPE html PUBLIC \"-\/\/W3C\/\/DTD HTML 4.0 Transitional\/\/EN\" \"http:\/\/www.w3.org\/TR\/REC-html40\/loose.dtd\">\n<?xml encoding=\"utf-8\" ?><html><body><div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button is-size-small\" href=\"https:\/\/clleancode.top\/travere-redesign\/event\/asn-kidney-week-2024\/\">Learn more<\/a><\/div>\n<\/body><\/html>\n<\/div>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-fe9cc265 wp-block-group-is-layout-flex\" style=\"margin-left:0px\">\n<div style=\"height:20px;width:0px\" aria-hidden=\"true\" class=\"wp-block-spacer wp-container-content-62aae154\"><\/div>\n<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer paragraph-border\"><\/div>\n\n\n\n<div class=\"newsletter\">\n\t<div class=\"newsletter-icon\">\n\t\t<span class=\"icon2-newsletter\"><\/span>\n\t<\/div>\n\t<div class=\"newsletter-text\">\n\t\t<p><strong>Sign up<\/strong> to receive scientific<br \/>\nupdates for healthcare professionals<br \/>\nfrom Travere Therapeutics.<\/p>\n\t<\/div>\n\t<div class=\"newsletter-form\">\n\t\t<script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\nvar gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),document.addEventListener(\"gform\/theme\/scripts_loaded\",function(){gform.themeScriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>\"function\"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn(\"The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1.\"),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener(\"gform_main_scripts_loaded\",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener(\"gform\/theme\/scripts_loaded\",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener(\"DOMContentLoaded\",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook(\"action\",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook(\"filter\",o,r,e,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,r){gform.removeHook(\"action\",o,r)},removeFilter:function(o,r,e){gform.removeHook(\"filter\",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+\"_\"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==r?t.apply(null,e):e[0]=t.apply(null,e)})),\"filter\"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});\n\/* ]]> *\/\n<\/script>\n\n                <div class='gf_browser_gecko gform_wrapper gform-theme gform-theme--foundation gform-theme--framework gform-theme--orbital' data-form-theme='orbital' data-form-index='0' id='gform_wrapper_1' ><style>#gform_wrapper_1[data-form-index=\"0\"].gform-theme,[data-parent-form=\"1_0\"]{--gf-color-primary: #204ce5;--gf-color-primary-rgb: 32, 76, 229;--gf-color-primary-contrast: #fff;--gf-color-primary-contrast-rgb: 255, 255, 255;--gf-color-primary-darker: #001AB3;--gf-color-primary-lighter: #527EFF;--gf-color-secondary: #fff;--gf-color-secondary-rgb: 255, 255, 255;--gf-color-secondary-contrast: #112337;--gf-color-secondary-contrast-rgb: 17, 35, 55;--gf-color-secondary-darker: #F5F5F5;--gf-color-secondary-lighter: #FFFFFF;--gf-color-out-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-out-ctrl-light-rgb: 17, 35, 55;--gf-color-out-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-out-ctrl-light-lighter: #F5F5F5;--gf-color-out-ctrl-dark: #585e6a;--gf-color-out-ctrl-dark-rgb: 88, 94, 106;--gf-color-out-ctrl-dark-darker: #112337;--gf-color-out-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-color-in-ctrl: #fff;--gf-color-in-ctrl-rgb: 255, 255, 255;--gf-color-in-ctrl-contrast: #112337;--gf-color-in-ctrl-contrast-rgb: 17, 35, 55;--gf-color-in-ctrl-darker: #F5F5F5;--gf-color-in-ctrl-lighter: #FFFFFF;--gf-color-in-ctrl-primary: #204ce5;--gf-color-in-ctrl-primary-rgb: 32, 76, 229;--gf-color-in-ctrl-primary-contrast: #fff;--gf-color-in-ctrl-primary-contrast-rgb: 255, 255, 255;--gf-color-in-ctrl-primary-darker: #001AB3;--gf-color-in-ctrl-primary-lighter: #527EFF;--gf-color-in-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-in-ctrl-light-rgb: 17, 35, 55;--gf-color-in-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-in-ctrl-light-lighter: #F5F5F5;--gf-color-in-ctrl-dark: #585e6a;--gf-color-in-ctrl-dark-rgb: 88, 94, 106;--gf-color-in-ctrl-dark-darker: #112337;--gf-color-in-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-radius: 3px;--gf-font-size-secondary: 14px;--gf-font-size-tertiary: 13px;--gf-icon-ctrl-number: url(\"data:image\/svg+xml,%3Csvg width='8' height='14' viewBox='0 0 8 14' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M4 0C4.26522 5.96046e-08 4.51957 0.105357 4.70711 0.292893L7.70711 3.29289C8.09763 3.68342 8.09763 4.31658 7.70711 4.70711C7.31658 5.09763 6.68342 5.09763 6.29289 4.70711L4 2.41421L1.70711 4.70711C1.31658 5.09763 0.683417 5.09763 0.292893 4.70711C-0.0976311 4.31658 -0.097631 3.68342 0.292893 3.29289L3.29289 0.292893C3.48043 0.105357 3.73478 0 4 0ZM0.292893 9.29289C0.683417 8.90237 1.31658 8.90237 1.70711 9.29289L4 11.5858L6.29289 9.29289C6.68342 8.90237 7.31658 8.90237 7.70711 9.29289C8.09763 9.68342 8.09763 10.3166 7.70711 10.7071L4.70711 13.7071C4.31658 14.0976 3.68342 14.0976 3.29289 13.7071L0.292893 10.7071C-0.0976311 10.3166 -0.0976311 9.68342 0.292893 9.29289Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-select: url(\"data:image\/svg+xml,%3Csvg width='10' height='6' viewBox='0 0 10 6' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M0.292893 0.292893C0.683417 -0.097631 1.31658 -0.097631 1.70711 0.292893L5 3.58579L8.29289 0.292893C8.68342 -0.0976311 9.31658 -0.0976311 9.70711 0.292893C10.0976 0.683417 10.0976 1.31658 9.70711 1.70711L5.70711 5.70711C5.31658 6.09763 4.68342 6.09763 4.29289 5.70711L0.292893 1.70711C-0.0976311 1.31658 -0.0976311 0.683418 0.292893 0.292893Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-search: url(\"data:image\/svg+xml,%3Csvg width='640' height='640' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath d='M256 128c-70.692 0-128 57.308-128 128 0 70.691 57.308 128 128 128 70.691 0 128-57.309 128-128 0-70.692-57.309-128-128-128zM64 256c0-106.039 85.961-192 192-192s192 85.961 192 192c0 41.466-13.146 79.863-35.498 111.248l154.125 154.125c12.496 12.496 12.496 32.758 0 45.254s-32.758 12.496-45.254 0L367.248 412.502C335.862 434.854 297.467 448 256 448c-106.039 0-192-85.962-192-192z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-label-space-y-secondary: var(--gf-label-space-y-md-secondary);--gf-ctrl-border-color: #686e77;--gf-ctrl-size: var(--gf-ctrl-size-md);--gf-ctrl-label-color-primary: #112337;--gf-ctrl-label-color-secondary: #112337;--gf-ctrl-choice-size: var(--gf-ctrl-choice-size-md);--gf-ctrl-checkbox-check-size: var(--gf-ctrl-checkbox-check-size-md);--gf-ctrl-radio-check-size: var(--gf-ctrl-radio-check-size-md);--gf-ctrl-btn-font-size: var(--gf-ctrl-btn-font-size-md);--gf-ctrl-btn-padding-x: var(--gf-ctrl-btn-padding-x-md);--gf-ctrl-btn-size: var(--gf-ctrl-btn-size-md);--gf-ctrl-btn-border-color-secondary: #686e77;--gf-ctrl-file-btn-bg-color-hover: #EBEBEB;--gf-field-img-choice-size: var(--gf-field-img-choice-size-md);--gf-field-img-choice-card-space: var(--gf-field-img-choice-card-space-md);--gf-field-img-choice-check-ind-size: var(--gf-field-img-choice-check-ind-size-md);--gf-field-img-choice-check-ind-icon-size: var(--gf-field-img-choice-check-ind-icon-size-md);--gf-field-pg-steps-number-color: rgba(17, 35, 55, 0.8);}<\/style><div id='gf_1' class='gform_anchor' tabindex='-1'><\/div>\n                        <div class='gform_heading'>\n\t\t\t\t\t\t\t<p class='gform_required_legend'>&quot;<span class=\"gfield_required gfield_required_asterisk\">*<\/span>&quot; indicates required fields<\/p>\n                        <\/div><form method='post' enctype='multipart\/form-data' target='gform_ajax_frame_1' id='gform_1'  action='\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/5345#gf_1' data-formid='1' novalidate>\n                        <div class='gform-body gform_body'><div id='gform_fields_1' class='gform_fields top_label form_sublabel_above description_below validation_below'><div id=\"field_1_2\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_2'>First Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_1_2' type='text' value='' class='large'    placeholder='First Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_3\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_3'>Last Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_3' id='input_1_3' type='text' value='' class='large'    placeholder='Last Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_1\" class=\"gfield gfield--type-email gfield--input-type-email gfield--width-full gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_1'>Email<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_1' id='input_1_1' type='email' value='' class='medium'   placeholder='Your Email' aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/div><div id=\"field_1_4\" class=\"gfield gfield--type-captcha gfield--input-type-captcha gfield--width-full field_sublabel_above gfield--no-description field_description_below field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label screen-reader-text' for='input_1_4'><\/label><div id='input_1_4' class='ginput_container ginput_recaptcha' data-sitekey='6LdC-_4qAAAAAFq7fXBVZpv8VBlO518KAQ92yXpY'  data-theme='light' data-tabindex='-1' data-size='invisible' data-badge='bottomright'><\/div><\/div><\/div><\/div>\n        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_1' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Subscribe Now'  \/> <input type='hidden' name='gform_ajax' value='form_id=1&amp;title=&amp;description=&amp;tabindex=0&amp;theme=orbital&amp;styles=[]&amp;hash=19a707562f078a6ce83770354aeb3dd2' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_1' value='iframe' \/>\n            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_1' id='gform_theme_1' value='orbital' \/>\n            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_1' id='gform_style_settings_1' value='[]' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_1' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='1' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_1' value='WyJbXSIsIjY5OGM1NmFiMTIxOTFmZGIyYmVmMjY3YTI3NzY4MjVkIl0=' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_1' id='gform_target_page_number_1' value='0' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_1' id='gform_source_page_number_1' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <\/form>\n                        <\/div>\n\t\t                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_1' id='gform_ajax_frame_1' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'><\/iframe>\n\t\t                <script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n gform.initializeOnLoaded( function() {gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery('#gform_ajax_frame_1').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_1');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_1').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_1').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_1').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_1').removeClass('gform_validation_error');}setTimeout( function() { \/* delay the scroll by 50 milliseconds to fix a bug in chrome *\/ jQuery(document).scrollTop(jQuery('#gform_wrapper_1').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_1').val();gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery(document).trigger('gform_page_loaded', [1, current_page]);window['gf_submitting_1'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_1').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_1').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [1]);window['gf_submitting_1'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_1').text());}else{jQuery('#gform_1').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger(\"gform_pre_post_render\", [{ formId: \"1\", currentPage: \"current_page\", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( \"gform_wrapper_1\" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( \"span\" );            visibilitySpan.id = \"gform_visibility_test_1\";            gformWrapperDiv.insertAdjacentElement( \"afterend\", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( \"gform_visibility_test_1\" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 1, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); \n\/* ]]> *\/\n<\/script>\n\t\t<div class=\"agreement\">\n\t\t\t<div id=\"agreement-box-newsletter\">\n\t\t\t\t<input type=\"checkbox\" id=\"agreement-check-newsletter\" \/>\n\t\t\t\t<label for=\"agreement-check-newsletter\"><\/label>\n\t\t\t\t<div id=\"agreement-box-tick-newsletter\">\n\t\t\t\t\t<span class=\"icon2-tick\"><\/span>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p>I understand that by checking this box and clicking &#8220;Subscribe now&#8221; I am submitting my contact information and I consent to receive company communications from Travere Therapeutics.<\/p>\n\t\t\t\t<p>All personal information will be processed by or on behalf of Travere to provide access to company information and engage in marketing activities. Travere will retain personal information only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal information is private and will not sell this personal information or disseminate it to third parties who are not providing services to Travere. You may unsubscribe at any time. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\" rel=\"noopener\">Travere  privacy policies<\/a>.<\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div id=\"invalid-newsletter\" class=\"invalid\">\n\t\t\t<div id=\"invalid-box-newsletter\">\n\t\t\t\t<span class=\"icon2-info-fill\"><\/span>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p><strong>Invalid email address.<\/strong><br \/>\n\t\t\t\tMake sure email is in correct format: <a href=\"\">name@example.com<\/a><\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:45px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-ocean-blue-color has-text-color has-link-color wp-elements-ae2998e762e75c059bf0a550d3f8cbfa\" style=\"margin-bottom:calc(30px * var(--scale))\"><strong>Footnotes<\/strong><\/h5>\n\n\n\n<p class=\"has-small-font-size\" style=\"padding-bottom:calc(30px * var(--scale))\">CR, complete remission; eGFR, estimated glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; MMRM, mixed models for repeated measures; RASi, renin-angiotensin system inhibitor; UPE, urinary protein excretion; UPCR, urine protein-creatinine ratio.<\/p>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">Inker LA et al. <em>Am J Kidney Dis<\/em>. 2016;68(3):392-401.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Reich HN et al. <em>J Am Soc Nephrol<\/em>. 2007;18(12):3177-3183.<\/li>\n\n\n\n<li class=\"has-small-font-size\">KDIGO Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Accessed 22 October 2024. <a href=\"https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf\">https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf<\/a><\/li>\n\n\n\n<li class=\"has-small-font-size\">Pitcher D et al. <em>Clin J Am Soc Nephrol<\/em>. 2023;18(6):727-738.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Heerspink JLH et al. Poster presented at: American Society of Nephrology 2024; October 23-27, 2024; San Diego, USA. FR-PO872.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kooienga I et al. Poster presented at: American Society of Nephrology 2024; October 23-27, 2024; San Diego, USA. FR-OR57.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Cheung CK et al. Presented at: American Society of Nephrology 2024; October 23-27, 2024; San Diego, USA. FR-OR63.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rovin BH et al. <em>Lancet<\/em>. 2023;402(10417):2077-2090.<\/li>\n<\/ol>\n<\/div>\n\n\n<p class=\"has-text-align-right has-small-font-size\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\">MA-SP-24-0176 | December 2024<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":5410,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":""},"product":[78],"therapeutic_area":[97],"disease_area":[174],"study_registry":[175,188],"study_type":[176],"resource_type":[208],"class_list":["post-5345","rkd-news","type-rkd-news","status-publish","has-post-thumbnail","hentry","product-spa","therapeutic_area-neph","disease_area-igan","study_registry-protect","study_registry-spartan","study_type-clinical","resource_type-newsletter"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rare Kidney Disease News | ASN 2024 Spotlight | Travere Medical Affairs<\/title>\n<meta name=\"description\" content=\"Learn more about sparsentan achieving complete remission of proteinuria, a treatment goal in the draft 2024 KDIGO guideline. Read now.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy\" \/>\n<meta property=\"og:description\" content=\"Learn more about sparsentan achieving complete remission of proteinuria, a treatment goal in the draft 2024 KDIGO guideline. Read now.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T13:10:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/asn-2024-spotlight-sparsentan-complete-remission\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/asn-2024-spotlight-sparsentan-complete-remission\\\/\",\"name\":\"Rare Kidney Disease News | ASN 2024 Spotlight | Travere Medical Affairs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/asn-2024-spotlight-sparsentan-complete-remission\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/asn-2024-spotlight-sparsentan-complete-remission\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/graph-magnifying-glass_header.png\",\"datePublished\":\"2024-12-17T00:11:44+00:00\",\"dateModified\":\"2025-10-14T13:10:27+00:00\",\"description\":\"Learn more about sparsentan achieving complete remission of proteinuria, a treatment goal in the draft 2024 KDIGO guideline. Read now.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/asn-2024-spotlight-sparsentan-complete-remission\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/asn-2024-spotlight-sparsentan-complete-remission\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/asn-2024-spotlight-sparsentan-complete-remission\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/graph-magnifying-glass_header.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/graph-magnifying-glass_header.png\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/asn-2024-spotlight-sparsentan-complete-remission\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASN 2024 Spotlight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rare Kidney Disease News | ASN 2024 Spotlight | Travere Medical Affairs","description":"Learn more about sparsentan achieving complete remission of proteinuria, a treatment goal in the draft 2024 KDIGO guideline. Read now.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy","og_description":"Learn more about sparsentan achieving complete remission of proteinuria, a treatment goal in the draft 2024 KDIGO guideline. Read now.","og_url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-14T13:10:27+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/","url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/","name":"Rare Kidney Disease News | ASN 2024 Spotlight | Travere Medical Affairs","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png","datePublished":"2024-12-17T00:11:44+00:00","dateModified":"2025-10-14T13:10:27+00:00","description":"Learn more about sparsentan achieving complete remission of proteinuria, a treatment goal in the draft 2024 KDIGO guideline. Read now.","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"ASN 2024 Spotlight"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-27 11:00:39","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"therapeutic_area","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/5345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/rkd-news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/5410"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=5345"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=5345"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=5345"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=5345"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=5345"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=5345"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=5345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}